ArticleTranslational lung cancer research2025
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC).
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the therapeutic advancements achieved through immunotherapy [immune checkpoint inhibitors (ICIs)] in treating advanced non-small cell lung cancer (NSCLC), the majority of patients will experience tumor progression. There is an urgent need for new predictive biomarkers of ICI efficacy in this setting. Our study aims to demonstrate the role of gut leakage, evaluated by plasma citrulline, and bacterial translocation, through blood microbiome assessment, as predictive markers of response to ICIs in advanced NSCLC. Methods: We used two independent cohorts (n=89 and n=85) of patients treated with ICIs for advanced NSCLC, with prospective blood citrulline assays at baseline (T0), 1st follow-up (T1) and progression (T2), by ion exchange chromatography. Early use of antibiotics and other demographic data were also collected. Quantification of 16sRNA gene expression and qualitative analysis of the blood microbiome were also performed. We correlated these biomarkers with ICI efficacy. Results: In the first cohort, blood citrulline levels were available for 75 patients at baseline (T0), with 35 patients with low citrulline level (<28 µM) and 40 patients with high citrulline level (≥28 µM). High baseline citrulline level (T0) was linked to a reduced refractory rate (P=0.001), improved response rate (P=0.001), a higher clinical benefit rate (P=0.009), and better progression-free survival (PFS) and overall survival (OS). Median PFS was 27.8 months in patients with baseline high citrulline level, and 7.5 months in patients with low citrulline level (P=0.04); median OS was 55.9 and 24.17 months (P=0.008). Those results remained consistent in the validation cohort. Responder patients had also lower levels of bacterial 16sRNA in their blood at T0 (P=0.01). Conclusions: Our study supports the potential utility of citrulline and quantification of 16sRNA in blood as predictive biomarkers for response to ICIs in treatment of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.